

Manually Signed

FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL table with OMB Number: 3235-0076, Expires: May 31, 2005, Estimated average burden hours per response: 16.00



03023731

FORM D


NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

SEC USE ONLY table with Prefix, Serial, and DATE RECEIVED fields

Name of Offering (Biofisica LLC), Filing Under (Rule 506 checked), Type of Filing (Amendment checked)

A. BASIC IDENTIFICATION DATA


1. Enter the information requested about the issuer. Name of Issuer (Biofisica, LLC), Address of Executive Offices (1961 Travers Circle, Lawrenceville, Ga. 30044), Telephone Number ((770) 962-1400)



development and sale of wound healing products based on electrical stimulation technology

Type of Business Organization (other checked: limited liability company)

Actual or Estimated Date of Incorporation of Organization: 10/00, Actual checked, Jurisdiction of Incorporation or Organization: GA



GENERAL INSTRUCTIONS

Federal: Who Must File, When To File, Where To File, Copies Required, Information Required, Filing Fee

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is pre-dictated on the filing of a federal notice.

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if the answer is "none" or "zero". If the transaction is an exchange offering check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

Type of Security	Aggregate Offering Price	Amount Already Sold
Debt	\$ 0	\$ 0
Equity	\$ 0	\$ 0
<input type="checkbox"/> Common <input type="checkbox"/> Preferred		
Convertible Securities (including warrants)	\$ 0	\$ 0
Partnership Interests	\$ 0	\$ 0
Other (Specify <u>LLC Membership Interests - Series B</u>)	\$ 1,150,000	\$ 700,000
Total	<u>1,150,000</u>	<u>\$ 700,000</u>

Answer also in Appendix, Column 3, if filing under ULOE.

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if the answer is "none" or "zero".

	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors	9	\$ 700,000
Non-accredited Investors	0	\$ 0
Total (for filings under Rule 504 only)		\$

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this is filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.

Type of Offering	Type of Security	Dollar Amount Sold
Rule 505	n/a	\$
Regulation A	n/a	\$
Rule 504	n/a	\$
Total		\$

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

Transfer Agent's Fees	<input type="checkbox"/>	\$ 0
Printing and Engraving Costs	<input checked="" type="checkbox"/>	\$ 425
Legal Fees	<input checked="" type="checkbox"/>	\$ 49,250
Accounting Fees	<input type="checkbox"/>	\$ 0
Engineering Fees	<input type="checkbox"/>	\$ 0
Sales Commissions (specify finders' fees separately)	<input type="checkbox"/>	\$ 0
Other Expenses (identify <u>Blue Sky Filings (\$325)</u>)	<input checked="" type="checkbox"/>	\$ 325
Total	<input checked="" type="checkbox"/>	<u>\$ 50,000</u>

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS


b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." \$ 1,100,000

5. Indicate below the amount of the adjusted gross proceed to the issuer used or proposed to be Used for each of the purposes shown. If the amount for any purpose is not known, furnish an Estimate and check the box to the left of the estimate. The total of the payments listed must equal The adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

	Payments to Officers, Directors, & Affiliates	Payments to Others
Salaries and Fees	<input checked="" type="checkbox"/> \$ <u>5,000</u>	<input type="checkbox"/> \$ <u>0</u>
Purchase of real estate	<input type="checkbox"/> \$ <u>0</u>	<input type="checkbox"/> \$ <u>0</u>
Purchase, rental or leasing and installation of machinery and equipment	<input type="checkbox"/> \$ <u>0</u>	<input type="checkbox"/> \$ <u>0</u>
Construction or leasing of plant buildings and facilities	<input type="checkbox"/> \$ <u>0</u>	<input type="checkbox"/> \$ <u>0</u>
Acquisitions of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	<input type="checkbox"/> \$ <u>0</u>	<input type="checkbox"/> \$ <u>0</u>
Repayment of indebtedness	<input type="checkbox"/> \$ <u>0</u>	<input type="checkbox"/> \$ <u>0</u>
Working capital	<input type="checkbox"/> \$ <u>0</u>	<input checked="" type="checkbox"/> \$ <u>390,000</u>
Other (specify): <u>Research and Development (\$625,000);</u>	<input type="checkbox"/> \$ <u>0</u>	<input checked="" type="checkbox"/> \$ <u>705,000</u>
<u>Sales and Marketing (\$55,000); Operating Reserve (\$25,000)</u>		
.....	<input checked="" type="checkbox"/> \$ <u>5,000</u>	<input checked="" type="checkbox"/> \$ <u>1,095,000</u>

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) Biofisica, LLC	Signature 	Date 06/16/03
Name of Signer (Print or Type) Rafael V. Andino	Title of Signer (Print or Type) Manager	

ATTENTION

Intentional misstatements or omissions of fact constitutes federal criminal violations. (See 18 U.S.C. 1001.)